SOTIO Biotech Pipeline

SOTIO® is developing the next generation of potent immunotherapies for patients with cancer. With its in-house discovery efforts as well as it strategic licensing agreements with partners Cytune Pharma and NBE-Therapeutics, SOTIO is building a pipeline of attractive oncology programs. SOTIO’s scientific research, translational and clinical development expertise provides the infrastructure to translate early stage science into promising clinical stage assets.